REG - Abingdon Health PLC - Result of General Meeting and Total Voting Rights

Abingdon HealthAnnouncement

12/08/2024 10:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240812:nRSL0950Aa&default-theme=true

RNS Number : 0950A  Abingdon Health PLC  12 August 2024

12 August 2024

 

Abingdon Health plc

("Abingdon", the "Group", or the "Company")

Result of General Meeting and Total Voting Rights

Abingdon (AIM:ABDX), a leading international lateral flow contract
development and manufacturing organisation, is pleased to announce that, at
the General Meeting held earlier today, all resolutions as set out in its
Notice of General Meeting dated 24 July 2024 were duly passed.

Capitalised terms used but not otherwise defined in this announcement shall
have the meanings given to them in the Company's announcement made at 4:51
p.m. on 24 July 2024, unless the context requires otherwise.

Admission and Total Voting Rights

Following the General Meeting, the Company will allot and issue 53,589,741
Fundraising Shares.

Application has been made to the London Stock Exchange for admission of the
Fundraising Shares to trading on AIM. It is expected that Admission will
become effective and dealings in the Fundraising Shares will commence on AIM
at 8.00 a.m. on or around the 14 August 2024. The Fundraising Shares will
rank pari passu in all respects with existing ordinary shares of 2.5
pence each.

Following Admission, the total number of shares in the capital of the Company
in issue with voting rights will be 189,523,153 ordinary shares of 2.5
pence each. This figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, Abingdon under the
Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Result of the meeting

Details of the results of the voting (which was undertaken by way of a poll
vote) at the General Meeting are set out below. Resolution 1 was proposed and
passed as an ordinary resolution and resolution 2 was proposed and passed as a
special resolution.

                                                                                 For                          Against
                                                                                 Votes       % of votes cast  Votes    % of votes cast
 1. Authority to Allot Shares                                                    60,896,201  99.85%           92,916   0.15%
 2. Disapply the pre-emption rights provisions of section 561 of the Companies   60,886,201  99.83%           101,448  0.17%
 Act 2006 in respect of the allotment of the Consideration Shares, the Further
 Consideration Shares, the Placing Shares and the Retail Offer Shares.

 

The passing of the Resolutions is one of the conditions to completion of the
Fundraising, and as a result of the votes cast in their favour, that
particular condition has been satisfied.

For further enquiries:

 

 Abingdon Health plc                                           www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer
 Chris Hand, Non-Executive Chairman

 Zeus Capital Limited (Sole Broker and Nominated Adviser)        Tel: +44 (0) 20 7220 1666
 Chris Fielding / Isaac Hooper (Corporate Finance)
 Fraser Marshall (Corporate Broking)

 

The person responsible for arranging the release of this announcement on
behalf of the Company is Chris Yates, Chief Executive Officer of the Company.

 

About Abingdon Health plc

Abingdon Health is a leading lateral flow contract development and
manufacturing organisation ("CDMO") offering its services to an international
customer base across industry sectors that include clinical, animal health,
plant health, and environmental testing. Abingdon has the internal
capabilities to take projects from initial concept through to routine and
large-scale manufacturing; from "idea to commercial success".

The Company's CDMO division offers product development, regulatory support,
technology transfer and manufacturing services for customers looking to
develop new assays or transfer existing laboratory-based assays to a lateral
flow format. Abingdon aims to support the increase in need for rapid results
across many industries and locations; and produces lateral flow tests in areas
such as infectious disease and clinical testing, including companion
diagnostics, animal health and environmental testing. Faster access to results
allows for rapid decision making and targeted intervention; and can support
better outcomes.

Abingdon 's Abingdon Simply Test® range of self-tests is an e-commerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(http://www.abingdonsimplytest.com/) ® e-commerce site offers consumers a
range of information to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract services
customers with a potential route to market for self-tests. The Abingdon Simply
Test® range is also sold through international distributors and through other
channels in the UK and Ireland, such as pharmacy chains.

Founded in 2008, Abingdon is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREANPAFDNLEEA